MCID: LMY004
MIFTS: 59

Leiomyosarcoma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Leiomyosarcoma

MalaCards integrated aliases for Leiomyosarcoma:

Name: Leiomyosarcoma 12 72 49 55 51 41 14 69
Leiomyosarcomas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1967
MeSH 41 D007890
NCIt 46 C3158
Orphanet 55 ORPHA64720
MESH via Orphanet 42 D007890
UMLS via Orphanet 70 C0023269
ICD10 via Orphanet 33 C49.9
UMLS 69 C0023269

Summaries for Leiomyosarcoma

NIH Rare Diseases : 49 Leiomyosarcoma is a rare cancerous tumor that consists of smooth (involuntary) muscle cells. Leiomyosarcoma is a type of sarcoma. It spreads through the blood stream and can affect the lungs, liver, blood vessels, or any other soft tissue in the body. The exact cause of leiomyosarcoma is not known, although genetic and environmental factors appear to be involved. It is most often found in the uterus or abdomen. Last updated: 6/26/2015

MalaCards based summary : Leiomyosarcoma, also known as leiomyosarcomas, is related to cutaneous leiomyosarcoma and epithelioid leiomyosarcoma. An important gene associated with Leiomyosarcoma is CHEK2 (Checkpoint Kinase 2), and among its related pathways/superpathways are ERK Signaling and Phospholipase-C Pathway. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A malignant smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.

Wikipedia : 72 Leiomyosarcoma, also referred to as LMS, is a malignant (cancerous) smooth muscle tumor. A benign tumor... more...

Related Diseases for Leiomyosarcoma

Diseases in the Leiomyosarcoma family:

Inflammatory Leiomyosarcoma

Diseases related to Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 416)
# Related Disease Score Top Affiliating Genes
1 cutaneous leiomyosarcoma 33.6 ACTC1 DES FH VIM
2 epithelioid leiomyosarcoma 33.4 ACTC1 DES ENO2 VIM
3 small intestine leiomyosarcoma 33.2 IGF2 KIT
4 gastric leiomyosarcoma 32.9 ENO2 IGF2 KIT PDGFRA
5 gastrointestinal stromal tumor 30.7 ACTC1 DES ENO2 KIT PDGFRA PDGFRB
6 smooth muscle tumor 30.5 ACTC1 DES KIT PGR VIM
7 fibrous histiocytoma 30.5 ACTC1 DES VIM
8 uterine carcinosarcoma 30.4 KIT PGR TP53
9 leiomyoma 30.4 ACTC1 DES FH IGF2 PGR
10 leiomyomatosis 30.3 FH MED12 PGR
11 sarcoma 30.2 CHEK2 KIT MDM2 TP53
12 bizarre leiomyoma 30.2 ACTC1 MED12 PGR
13 angiosarcoma 30.2 KIT TP53 VIM
14 sarcoma, synovial 30.1 DES KIT MDM2 VIM
15 malignant giant cell tumor 30.0 ACTC1 S100B TP53
16 mesenchymoma 30.0 DES MB MDM2
17 li-fraumeni syndrome 2 29.9 CHEK2 TP53
18 cystadenocarcinoma 29.9 PGR TP53 VIM
19 syringocystadenoma papilliferum 29.8 ACTC1 DES S100B VIM
20 lipomatosis, multiple 29.8 CDK4 DES MDM2
21 liposarcoma 29.8 CDK4 DES MB MDM2 TP53 VIM
22 dedifferentiated liposarcoma 29.8 ACTC1 CDK4 DES MDM2 TP53
23 ovarian cancer 1 29.8 PGR TP53 WT1
24 histiocytoma 29.7 CDK4 KIT MB MDM2 TP53
25 desmoid tumor 29.7 KIT PDGFRA PDGFRB
26 angiomyoma 29.7 ENO2 KIT MB
27 myxoid liposarcoma 29.7 CDK4 MDM2 TP53
28 glomus tumor 29.6 ACTC1 DES ENO2 TP53 VIM
29 teratoma 29.6 ACTC1 ENO2 KIT TP53
30 epulis 29.6 DES ENO2 PGR VIM
31 granular cell tumor 29.6 DES ENO2 S100B VIM
32 neurofibromatosis, type iv, of riccardi 29.6 KIT PDGFRA S100B
33 li-fraumeni syndrome 29.5 CHEK2 MDM2 TP53
34 endometrial stromal sarcoma 29.3 ACTC1 DES KIT MB PDGFRB PGR
35 neurilemmoma 29.2 DES ENO2 KIT PDGFRA S100B VIM
36 embryonal rhabdomyosarcoma 29.0 CDK4 DES IGF2 MB MYOG
37 glioblastoma multiforme 29.0 CDK4 MDM2 PDGFRA PDGFRB TP53
38 glioblastoma 29.0 CDK4 MDM2 PDGFRA PDGFRB TP53
39 uterine sarcoma 29.0 DES KIT MB MDM2 PDGFRB WT1
40 dermatofibrosarcoma protuberans 28.8 ACTC1 DES PDGFRA PDGFRB S100B TP53
41 renal cell carcinoma, nonpapillary 28.5 ENO2 FH KIT PDGFRB VIM WT1
42 malignant mesenchymoma 28.4 CDK4 DES KIT MB MDM2 MYOG
43 rhabdomyosarcoma 28.3 CDK4 DES ENO2 IGF2 MB MDM2
44 lung leiomyosarcoma 12.2
45 uterus leiomyosarcoma 12.2
46 liver leiomyosarcoma 12.2
47 colon leiomyosarcoma 12.2
48 kidney leiomyosarcoma 12.1
49 extrahepatic bile duct leiomyosarcoma 12.1
50 anus leiomyosarcoma 12.0

Graphical network of the top 20 diseases related to Leiomyosarcoma:



Diseases related to Leiomyosarcoma

Symptoms & Phenotypes for Leiomyosarcoma

GenomeRNAi Phenotypes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

25 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.95 S100B WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.95 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.95 VIM
4 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.95 CHEK2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.95 CDK4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.95 CHEK2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.95 WT1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.95 CHEK2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.95 VIM
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.95 KIT WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.95 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.95 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.95 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.95 VIM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.95 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.95 VIM
17 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.95 CHEK2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.95 CDK4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.95 WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.95 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.95 VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.95 VIM KIT WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.95 WT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.95 CDK4 KIT
25 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.95 WT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.95 CDK4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.95 WT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.95 S100B VIM
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.95 CDK4 S100B VIM CHEK2 WT1 KIT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.95 KIT
31 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.95 KIT
32 Decreased substrate adherent cell growth GR00193-A-1 9.76 KIT
33 Decreased substrate adherent cell growth GR00193-A-2 9.76 KIT CDK4
34 Decreased substrate adherent cell growth GR00193-A-3 9.76 CDK4 CHEK2
35 Decreased substrate adherent cell growth GR00193-A-4 9.76 KIT CDK4 CHEK2
36 Increased cell viability after pRB stimulation GR00230-A-1 9.26 KIT PDGFRB CDK4 CHEK2

MGI Mouse Phenotypes related to Leiomyosarcoma:

43 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.53 MB KIT MDM2 IGF2 ACTC1 CHEK2
2 homeostasis/metabolism MP:0005376 10.48 MB KIT MDM2 IGF2 ACTC1 CHEK2
3 cardiovascular system MP:0005385 10.46 MB KIT IGF2 ACTC1 DES CDK4
4 behavior/neurological MP:0005386 10.43 IGF2 KIT DES ENO2 CDK4 PDGFRA
5 mortality/aging MP:0010768 10.42 IGF2 MB KIT CHEK2 ACTC1 DES
6 growth/size/body region MP:0005378 10.41 IGF2 MB KIT ACTC1 CAPN6 ENO2
7 embryo MP:0005380 10.4 MB KIT MDM2 IGF2 CDK4 MED12
8 muscle MP:0005369 10.35 MB KIT MDM2 IGF2 ACTC1 CAPN6
9 hematopoietic system MP:0005397 10.34 KIT IGF2 MB CHEK2 CDK4 PDGFRA
10 immune system MP:0005387 10.28 KIT IGF2 CDK4 CHEK2 MDM2 PDGFRB
11 endocrine/exocrine gland MP:0005379 10.27 KIT IGF2 CHEK2 CDK4 MDM2 PDGFRB
12 craniofacial MP:0005382 10.25 IGF2 KIT CAPN6 ENO2 MED12 MDM2
13 integument MP:0010771 10.22 KIT IGF2 CDK4 PDGFRA MDM2 MYOG
14 digestive/alimentary MP:0005381 10.19 KIT IGF2 CDK4 CAPN6 MDM2 PDGFRB
15 nervous system MP:0003631 10.17 KIT IGF2 CDK4 CHEK2 ENO2 MED12
16 normal MP:0002873 10.15 KIT ACTC1 CDK4 MED12 MDM2 MYOG
17 limbs/digits/tail MP:0005371 10.11 KIT IGF2 PDGFRA MED12 MDM2 PGR
18 neoplasm MP:0002006 10.06 KIT CHEK2 CDK4 PDGFRA MDM2 PGR
19 no phenotypic analysis MP:0003012 10.01 KIT IGF2 MYOG MDM2 PDGFRA PGR
20 renal/urinary system MP:0005367 9.91 IGF2 KIT CDK4 FH PDGFRA MDM2
21 reproductive system MP:0005389 9.85 KIT IGF2 CDK4 MDM2 PDGFRB PDGFRA
22 pigmentation MP:0001186 9.72 KIT CDK4 MDM2 PDGFRA TP53
23 respiratory system MP:0005388 9.61 IGF2 MB KIT ENO2 PDGFRA MYOG
24 skeleton MP:0005390 9.28 KIT IGF2 MED12 MYOG MDM2 PDGFRB

Drugs & Therapeutics for Leiomyosarcoma

Drugs for Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2 Liver Extracts Phase 4,Phase 3,Phase 1
3 Cola Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
6
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
7
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
10
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
11
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
12
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
13
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
14
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
15
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
16
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
19
Ondansetron Approved Phase 3 99614-02-5 4595
20
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
21
Cyproheptadine Approved Phase 3 129-03-3 2913
22
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
23
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
24
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
25 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
26 Alkylating Agents Phase 3,Phase 2,Phase 1
27 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
28 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
29 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
30 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
32 Anti-Infective Agents Phase 3,Phase 2,Phase 1
33 Antimitotic Agents Phase 3,Phase 2,Phase 1
34 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
35 Antimetabolites Phase 3,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Antiviral Agents Phase 3,Phase 2,Phase 1
38 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
39 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
40 Etoposide phosphate Phase 3,Phase 2
41 Antirheumatic Agents Phase 3,Phase 2,Phase 1
42 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
43 Adjuvants, Anesthesia Phase 3
44 Analgesics Phase 3,Phase 1
45 Analgesics, Opioid Phase 3
46 Anesthetics Phase 3
47 Anesthetics, General Phase 3
48 Anesthetics, Intravenous Phase 3
49 Central Nervous System Depressants Phase 3
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 146)

# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
4 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
8 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
10 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
11 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
12 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
15 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
16 A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL 3818;Dacarbazine
17 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
18 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
19 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
20 A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Active, not recruiting NCT01692678 Phase 3 Trabectedin;Dacarbazine
21 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
22 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
23 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
24 Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma Not yet recruiting NCT02997358 Phase 3 Doxorubicin;Trabectedin
25 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
26 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
27 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
28 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
29 Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas Unknown status NCT01442662 Phase 2 pazopanib + gemcitabine
30 Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
31 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
32 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
33 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
34 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
35 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
36 SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma Completed NCT02303262 Phase 2 Mocetinostat;Gemcitabine
37 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Completed NCT00856050 Phase 2 letrozole
38 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
39 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Completed NCT00282087 Phase 2 gemcitabine, docetaxel, doxorubicin
40 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Completed NCT01220609 Phase 2 Ixabepilone
41 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
42 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2 trabectedin
43 Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma Completed NCT00310518 Phase 2 ARQ 501
44 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
45 Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
46 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
47 A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone
48 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2 Thalidomide
49 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
50 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride

Search NIH Clinical Center for Leiomyosarcoma

Cochrane evidence based reviews: leiomyosarcoma

Genetic Tests for Leiomyosarcoma

Anatomical Context for Leiomyosarcoma

MalaCards organs/tissues related to Leiomyosarcoma:

38
Uterus, Smooth Muscle, Liver, Lung, Breast, Bone, Colon

Publications for Leiomyosarcoma

Articles related to Leiomyosarcoma:

(show top 50) (show all 1232)
# Title Authors Year
1
Radiation-induced leiomyosarcoma of the rectum after cervical cancer treatment. ( 29439826 )
2018
2
Primary leiomyosarcoma in the colon: A case report. ( 29443772 )
2018
3
Options for Adjuvant Therapy for Uterine Leiomyosarcoma. ( 29417238 )
2018
4
Neuropilin 1 in uterine leiomyosarcoma. Clinical and pathological analysis. ( 29411340 )
2018
5
Denosumab as a potential therapeutic option for leiomyosarcoma with osteoclast-like giant cells: A case report. ( 29387393 )
2018
6
Primary pulmonary leiomyosarcoma: A population-based study. ( 29413053 )
2018
7
Leiomyosarcoma of the stomach with metastasis to the liver: a case report with review of the literature. ( 29379638 )
2018
8
Metastatic leiomyosarcoma presenting as a lung mass with left atrial extension: case report and anesthetic management. ( 29403281 )
2018
9
A rare primary leiomyosarcoma of the parotid gland: A case report and literature review. ( 29395283 )
2018
10
Delayed diagnosis of dermal leiomyosarcoma mimicking keloid scar. ( 29374640 )
2018
11
Pazopanib-mediated Long-term Disease Stabilization after Local Recurrence and Distant Metastasis of Primary Intracranial Leiomyosarcoma: A Case Report on the Efficacy of Pazopanib as a Salvage Therapy. ( 29354331 )
2018
12
Primary Renal Leiomyosarcoma Presenting with Subcutaneous and Osseous Metastases: Staging and Follow-Up with 18F-FDG PET/CT. ( 29391915 )
2018
13
Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma. ( 29399140 )
2018
14
Diagnosis and management of rare inferior vena cava leiomyosarcoma guided by a novel minimally invasive vascular biopsy technique. ( 29411530 )
2018
15
A Case Report of Metastatic Primary Thyroid Leiomyosarcoma Treated with Pazopanib. ( 29431311 )
2018
16
Efficacy of Paclitaxel in a Patient with Inoperable Pulmonary Vein Leiomyosarcoma. ( 28868013 )
2017
17
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen. ( 28774898 )
2017
18
Surgery for recurrence in retroperitoneal leiomyosarcoma: Is it all about selection? ( 28672078 )
2017
19
Unexpected uterine leiomyosarcoma in a woman with multiple myomas treated with ulipristal acetate: case report and literature review. ( 28933575 )
2017
20
Eyelid metastasis as presenting feature of disseminated leiomyosarcoma - A rare case report. ( 28860921 )
2017
21
A Rare Intramedullary Spinal Cord Metastasis from a Retroperitoneal Leiomyosarcoma Presenting as a Non-Traumatic Spinal Cord Injury. ( 28628542 )
2017
22
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. ( 28641307 )
2017
23
Cutaneous Leiomyosarcoma of the Face. ( 28913324 )
2017
24
Recurrent Leiomyosarcoma of External Oblique Muscle Detected on 99mTc-MDP SPECT/CT. ( 28806250 )
2017
25
Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma. ( 28288693 )
2017
26
Cutaneous Leiomyosarcoma: On the Importance of Histologic Location. ( 29233527 )
2017
27
Pearly Facial Nodule as a Presentation of Late Metastasis of Retroperitoneal Leiomyosarcoma. ( 28858929 )
2017
28
Pulmonary Artery Leiomyosarcoma Diagnosed by Magnetic Resonance, PET-CT and EBUS-TBNA. ( 28314632 )
2017
29
Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. ( 28426279 )
2017
30
Pulmonary metastasis from uterine leiomyosarcoma in a patient with limited cutaneous systemic scleroderma. ( 29264076 )
2017
31
Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma. ( 28552535 )
2017
32
Rare case of primary leiomyosarcoma of sigmoid mesocolon. ( 28918402 )
2017
33
Leiomyosarcoma of inferior vena cava with intracardiac extension presenting as Budd-Chiari syndrome: Report of a rare case. ( 28631648 )
2017
34
Biatrial High-Grade Leiomyosarcoma With Nine-Year Post-Surgical Survival. ( 28007271 )
2017
35
Paratesticular Leiomyosarcoma: A Case Report and Review of the Literature. ( 28083483 )
2017
36
Gingival Leiomyosarcoma in a Young Woman: Case report and literature review. ( 29372093 )
2017
37
Coincidence or not? A rare case of rectal leiomyosarcoma amidst incidental findings of anal squamous cell carcinoma: case presentation and literature review. ( 28959428 )
2017
38
Myxoid leiomyosarcoma of the uterus: a clinicopathological and immunohistochemical study of 10 cases. ( 27717885 )
2017
39
Conjunctival leiomyosarcoma: A fairly common tumour in an uncommon site. ( 28835829 )
2017
40
Case Report: A Low-grade Uterine Leiomyosarcoma Showing Multiple Genetic Aberrations Including a Bi-allelic Loss of the Retinoblastoma Gene Locus, as well as Germ-line Uniparental Disomy for Part of the Long Arm of Chromosome 22. ( 28476787 )
2017
41
Cutaneous Leiomyosarcoma with Multiple Visceral Metastases in a Domestic Pigeon. ( 28665730 )
2017
42
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. ( 27900663 )
2017
43
Inflammatory leiomyosarcoma is a distinct tumor characterized by near-haploidization, few somatic mutations, and a primitive myogenic gene expression signature. ( 28884746 )
2017
44
Transanal total mesorectal excision for a large leiomyosarcoma at the lower rectum: a case report and literature review. ( 28092017 )
2017
45
A Case of Renal Metastasis of Uterine Leiomyosarcoma. ( 28944109 )
2017
46
Orbital leiomyosarcoma metastasis presenting prior to diagnosis of the primary tumor. ( 29403338 )
2017
47
Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment. ( 28893210 )
2017
48
Free disease long-term survival in primary thoracic spine leiomyosarcoma after total en bloc spondylectomy: A case report. ( 28898798 )
2017
49
Laparoscopically assisted resection of a primary hepatic leiomyosarcoma: A safe approach in a rare malignancy. ( 28065534 )
2017
50
Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study. ( 29353974 )
2017

Variations for Leiomyosarcoma

ClinVar genetic disease variations for Leiomyosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Pathogenic rs555607708 GRCh37 Chromosome 22, 29091857: 29091857

Cosmic variations for Leiomyosarcoma:

9 (show top 50) (show all 71)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11476 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.452C>A p.P151H 9
2 COSM11658 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.955A>T p.K319* 9
3 COSM10648 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.524G>A p.R175H 9
4 COSM44567 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.647T>C p.V216A 9
5 COSM10726 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.856G>A p.E286K 9
6 COSM10758 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.659A>G p.Y220C 9
7 COSM44683 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.652G>A p.V218M 9
8 COSM43778 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.713G>T p.C238F 9
9 COSM43827 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.581T>C p.L194P 9
10 COSM44073 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.374C>A p.T125K 9
11 COSM10943 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.841G>C p.D281H 9
12 COSM10690 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>A p.R158H 9
13 COSM43871 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.746G>T p.R249M 9
14 COSM44956 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.808T>G p.F270V 9
15 COSM11224 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.394A>C p.K132Q 9
16 COSM43878 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.427G>A p.V143M 9
17 COSM43632 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.493C>T p.Q165* 9
18 COSM10705 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.586C>T p.R196* 9
19 COSM10662 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.743G>A p.R248Q 9
20 COSM44238 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.631A>G p.T211A 9
21 COSM43700 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.712T>A p.C238S 9
22 COSM43949 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.401T>G p.F134C 9
23 COSM10656 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.742C>T p.R248W 9
24 COSM44076 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.655C>T p.P219S 9
25 COSM10905 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.451C>T p.P151S 9
26 COSM10768 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.535C>T p.H179Y 9
27 COSM10790 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.455C>T p.P152L 9
28 COSM10788 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.764T>G p.I255S 9
29 COSM44960 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.708C>G p.Y236* 9
30 COSM10891 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.814G>A p.V272M 9
31 COSM5152 PTEN soft tissue,smooth muscle,leiomyosarcoma,NS c.388C>T p.R130* 9
32 COSM5124 PTEN soft tissue,smooth muscle,leiomyosarcoma,NS c.1202C>T p.T401I 9
33 COSM5923 PTEN soft tissue,smooth muscle,leiomyosarcoma,NS c.1027-7T>C p.? 9
34 COSM5064 PTEN soft tissue,smooth muscle,leiomyosarcoma,NS c.44G>A p.R15K 9
35 COSM516 KRAS soft tissue,smooth muscle,leiomyosarcoma,NS c.34G>T p.G12C 9
36 COSM534 KRAS soft tissue,smooth muscle,leiomyosarcoma,NS c.38G>T p.G13V 9
37 COSM521 KRAS soft tissue,smooth muscle,leiomyosarcoma,NS c.35G>A p.G12D 9
38 COSM532 KRAS soft tissue,smooth muscle,leiomyosarcoma,NS c.38G>A p.G13D 9
39 COSM483 HRAS soft tissue,smooth muscle,leiomyosarcoma,NS c.35G>T p.G12V 9
40 COSM5731840 ATRX soft tissue,smooth muscle,leiomyosarcoma,NS c.6124C>T p.Q2042* 9
41 COSM5731841 ATRX soft tissue,smooth muscle,leiomyosarcoma,NS c.4543G>T p.E1515* 9
42 COSM5731844 ASXL1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1008G>T p.R336S 9
43 COSM43965 TP53 soft tissue,smooth muscle,leiomyoma,NS c.734G>C p.G245A 4
44 COSM43559 TP53 soft tissue,smooth muscle,leiomyoma,NS c.517G>T p.V173L 4
45 COSM6023961 PREX2 soft tissue,smooth muscle,leiomyoma,NS c.1170C>A p.C390* 4
46 COSM131595 MED12 soft tissue,smooth muscle,leiomyoma,NS c.131G>C p.G44A 4
47 COSM131592 MED12 soft tissue,smooth muscle,leiomyoma,NS c.130G>C p.G44R 4
48 COSM131596 MED12 soft tissue,smooth muscle,leiomyoma,NS c.131G>A p.G44D 4
49 COSM131597 MED12 soft tissue,smooth muscle,leiomyoma,NS c.131G>T p.G44V 4
50 COSM131590 MED12 soft tissue,smooth muscle,leiomyoma,NS c.107T>G p.L36R 4

Copy number variations for Leiomyosarcoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 102985 16 58400001 69400000 Loss Leiomyosarcoma

Expression for Leiomyosarcoma

Search GEO for disease gene expression data for Leiomyosarcoma.

Pathways for Leiomyosarcoma

Pathways related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 CAPN6 CDK4 CHEK2 IGF2 KIT MDM2
2
Show member pathways
13 IGF2 KIT MDM2 PDGFRA PDGFRB TP53
3
Show member pathways
12.98 CDK4 KIT MDM2 PDGFRA PDGFRB TP53
4
Show member pathways
12.8 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
5
Show member pathways
12.72 CDK4 IGF2 KIT PGR TP53
6 12.71 IGF2 KIT PDGFRA PDGFRB TP53
7
Show member pathways
12.65 KIT MDM2 PDGFRA PDGFRB TP53
8 12.4 MDM2 PDGFRA PDGFRB TP53 VIM
9 12.38 CDK4 CHEK2 MDM2 TP53 VIM
10
Show member pathways
12.32 CDK4 CHEK2 MDM2 TP53
11 12.32 CDK4 CHEK2 MDM2 TP53
12 12.28 CDK4 FH IGF2 KIT MDM2 PDGFRA
13 12.26 CDK4 CHEK2 PDGFRA PDGFRB TP53
14
Show member pathways
12.17 CDK4 CHEK2 MDM2 TP53
15
Show member pathways
12.16 CAPN6 CHEK2 MDM2 PDGFRA PDGFRB TP53
16 12.09 CDK4 CHEK2 MDM2 TP53
17
Show member pathways
12.08 CDK4 MDM2 PDGFRA PDGFRB TP53
18 12.06 CDK4 CHEK2 MDM2 TP53
19 11.96 CDK4 CHEK2 MDM2 TP53
20
Show member pathways
11.78 CHEK2 MDM2 TP53
21 11.74 PDGFRA S100B VIM
22 11.68 CDK4 MDM2 TP53
23
Show member pathways
11.68 CHEK2 MDM2 TP53
24 11.66 ACTC1 DES VIM
25
Show member pathways
11.58 KIT PDGFRA PDGFRB
26 11.55 CHEK2 MDM2 TP53
27 11.52 KIT PDGFRA PDGFRB TP53
28
Show member pathways
11.5 CHEK2 MDM2 TP53
29 11.39 ACTC1 IGF2 KIT PDGFRA
30 11.29 CDK4 CHEK2 MDM2 TP53
31 11.16 CDK4 MDM2 TP53
32 11.15 CDK4 IGF2 MDM2 PDGFRA PDGFRB TP53
33 11.1 CDK4 CHEK2 MDM2 TP53
34 10.93 DES IGF2 KIT PDGFRA PDGFRB VIM
35 10.27 CHEK2 TP53

GO Terms for Leiomyosarcoma

Cellular components related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 ACTC1 CAPN6 CDK4 DES ENO2 FH

Biological processes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 ACTC1 KIT MDM2 TP53 VIM
2 heart development GO:0007507 9.92 MB MDM2 MED12 WT1
3 protein autophosphorylation GO:0046777 9.86 CHEK2 KIT PDGFRA PDGFRB
4 positive regulation of protein kinase B signaling GO:0051897 9.83 IGF2 KIT PDGFRA PDGFRB
5 cell chemotaxis GO:0060326 9.79 KIT PDGFRA PDGFRB
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 KIT PDGFRA PDGFRB
7 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.75 CHEK2 MDM2 TP53
8 positive regulation of fibroblast proliferation GO:0048146 9.72 CDK4 PDGFRA PDGFRB
9 positive regulation of cell proliferation GO:0008284 9.7 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
10 positive regulation of cell cycle GO:0045787 9.67 CDK4 MDM2 TP53
11 muscle filament sliding GO:0030049 9.65 ACTC1 DES VIM
12 retina vasculature development in camera-type eye GO:0061298 9.61 PDGFRA PDGFRB
13 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.59 PDGFRA PDGFRB
14 metanephric mesenchyme development GO:0072075 9.58 PDGFRB WT1
15 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.58 KIT PDGFRA PDGFRB
16 metanephric S-shaped body morphogenesis GO:0072284 9.54 PDGFRB WT1
17 cellular response to gamma radiation GO:0071480 9.54 CHEK2 MDM2 TP53
18 metanephric glomerular capillary formation GO:0072277 9.51 PDGFRA PDGFRB
19 negative regulation of cell cycle arrest GO:0071157 9.5 CDK4 CHEK2 MDM2
20 cellular response to actinomycin D GO:0072717 9.46 MDM2 TP53
21 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.43 PDGFRA PDGFRB
22 response to hyperoxia GO:0055093 9.43 CDK4 PDGFRB TP53
23 cardiac myofibril assembly GO:0055003 9.13 ACTC1 PDGFRA PDGFRB
24 positive regulation of phospholipase C activity GO:0010863 8.8 KIT PDGFRA PDGFRB

Molecular functions related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 CHEK2 DES MDM2 PGR S100B TP53
2 nucleotide binding GO:0000166 9.65 CDK4 CHEK2 KIT PDGFRA PDGFRB
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 KIT PDGFRA PDGFRB
4 platelet-derived growth factor binding GO:0048407 9.4 PDGFRA PDGFRB
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 KIT PDGFRA PDGFRB
6 vascular endothelial growth factor binding GO:0038085 8.62 PDGFRA PDGFRB
7 protein binding GO:0005515 10.3 CDK4 CHEK2 DES ENO2 FH IGF2

Sources for Leiomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....